Shares of Questcor originally leaped over the 27% premium Mallinckrodt is paying, but the stock has pulled back some. Questcor is something of a one-trick pony. But it is a big trick. The company’s H.P. Acthar injectable gel has been …
As a result of defendants’ false statements, Questcor’s stock traded at artificially inflated prices during the Class Period, reaching a high of $57.64 per share on July 9, 2012. On September 19, 2012, Citron Research reported that Aetna Inc. …
Questcor's stock leapt nearly 40% during trading yesterday as investors welcomed its $135m-plus purchase of Novartis' rival immune drug Synacthen. The US speciality pharma said it has bought rights to develop Synacthen (tetracosactide) …
In a report published Tuesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating and $93.00 price target on Questcor Pharmaceuticals (NASDAQ: QCOR). In the report, Mizuho Securities USA noted, “In the wake of today's …
Questcor shareholders will receive $30.00 per share in cash and 0.897 Mallinckrodt shares for each share of Questcor common stock they own, for a total approximate consideration of $86.10 per Questcor share. Following completion of …
Questcor’s shares were trading at $77 on the Nasdaq on Monday afternoon. Mallinckrodt was down 6 percent at $58.50 on the New York Stock Exchange. The deal - the latest in a series of acquisitions structured to take advantage of Ireland’s …
After this news, Questcor’s stock plummeted 48 percent to close at $26.35 per share on Sept. 19, 2012, the suit states. Then Questcor announced the U.S. government had launched an investigation into the company’s promotional …
Under terms of the deal, shareholders of Questcor — formed in 1999 in the merger of Southern California companies RiboGene Inc. and Cypros Pharmaceutical Corp. — will be paid $30 in cash and 0.897 of a share of Mallinckrodt stock